期刊
CANCER AND METASTASIS REVIEWS
卷 35, 期 2, 页码 151-163出版社
SPRINGER
DOI: 10.1007/s10555-015-9601-1
关键词
Cyclin-dependent kinase; Sarcoma; Kinase inhibitor; Targeted therapy
类别
资金
- Gattegno and Wechsler funds
- Kenneth Stanton Fund
- Sarcoma Foundation of America (SFA)
- National Cancer Institute (NCI)/National Institutes of Health (NIH) [CA 151452-01]
- Sarcoma SPORE/NIH
- Academic Enrichment Fund of MGH Orthopaedics
Uncontrolled proliferation and cell growth is the hallmark of many different malignant diseases, including sarcomas. Cyclin-dependent kinases (CDKs) are members of the serine/threonine protein kinase family and play crucial roles in tumor cell proliferation and growth by controlling cell cycle, transcription, and RNA splicing. In addition, several CDKs influence multiple targets and phosphorylate transcription factors involved in tumorigenesis. There are many examples linking dysregulated activation and expression of CDKs to tumors, and targeting CDKs in tumor cells has become a promising therapeutic strategy. More recently, the Food and Drug Administration (FDA) has approved the CDK4/6 inhibitor palbociclib for treating metastatic breast cancer. In sarcomas, high levels of CDK mRNA and protein expression have been found in most human sarcoma cells and patient tissues. Many studies have demonstrated consistent results in which inhibition of different CDKs decrease sarcoma cell growth and induce apoptosis. Therefore, CDKs comprise an attractive set of targets for novel anti-sarcoma drug development. In this review, we discuss the roles of different members of CDKs in various sarcomas and provide a pre-clinical overview of promising therapeutic potentials of targeting CDKs with a special emphasis on sarcoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据